BPG is committed to discovery and dissemination of knowledge
Featured Articles
4/11/2024 2:43:04 PM | Browse: 526 | Download: 1278
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 88673
Country China
Received
2023-10-04 13:27
Peer-Review Started
2023-10-04 13:29
First Decision by Editorial Office Director
2023-12-18 08:41
Return for Revision
2023-12-18 08:41
Revised
2023-12-29 15:53
Publication Fee Transferred
Editorial Processing by Scientific Editor
2024-02-18 07:08
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2024-02-18 07:54
Articles in Press
2024-02-18 07:54
Edit the Manuscript by Language Editor
2024-02-05 16:50
Typeset the Manuscript
2024-03-04 09:29
Publish the Manuscript Online
2024-04-11 02:23
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Kun-Peng Ma, Jin-Xin Fu, Feng Duan and Mao-Qiang Wang
Funding Agency and Grant Number
Corresponding Author Mao-Qiang Wang, MD, PhD, Deputy Director, Department of Interventional Radiology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, No. 28 Fuxin Road, Haidian District, Beijing 100853, China. wangmaoqiang301@163.com
Key Words Transarterial chemoembolization; Efficacy; Lenvatinib; Programmed cell death protein-1 inhibitors; Unresectable hepatocellular carcinoma
Core Tip Transarterial chemoembolization/lenvatinib/programmed cell death protein-1 combined treatment was well tolerated with encouraging efficacy in unresectable hepatocellular carcinoma patients. The patients in Barcelona Clinic Liver Cancer Classification (BCLC) B, with early neutrophil-to-lymphocyte ratio (NLR) response (decrease) and early alpha fetoprotein (AFP) response (decrease > 20%) might achieve better clinical outcomes in the triple therapy. It is advisable that BCLC stage, NLR, and AFP should be considered within clinical decision-making in order to obtain better prognosis.
Publish Date 2024-04-11 02:23
Citation Ma KP, Fu JX, Duan F, Wang MQ. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(4): 1236-1247
URL https://www.wjgnet.com/1948-5204/full/v16/i4/1236.htm
DOI https://dx.doi.org/10.4251/wjgo.v16.i4.1236
Full Article (PDF) WJGO-16-1236-with-cover.pdf